Essure Removal for the Treatment of Device-Attributed Symptoms: An Expanded Case Series and Follow-up Survey


      Study Objective

      To evaluate perioperative outcomes and symptom resolution in women undergoing removal of the Essure device for device-attributed symptoms.


      Retrospective case series and follow-up patient survey (Canadian Task Force classification III).


      Large academic medical center.


      Fifty-two women who underwent laparoscopic or hysteroscopic Essure removal between 2012 and 2016.


      Women underwent one of four procedures: laparoscopic hysterectomy (LH) and bilateral salpingectomy (BS), laparoscopic BS and cornuectomy, laparoscopic Essure removal and BS, or hysteroscopic Essure removal and laparoscopic BS.

      Measurements and Main Results

      Fifty-two women who underwent Essure removal were asked to complete a survey regarding symptom resolution and quality of life following the procedure. Thirty-two women (61.5%) responded to the survey. Seventy-five percent (24/32) reported almost total or total improvement in quality of life, 56.3% (18/32) for sex life, 53.1% (17/32) for pelvic pain, and 65.6% (21/32) for daily activities. The majority of women reported some degree of improvement in all four domains queried (87.5%, 28/32). When asked about their symptoms in general, 31.3% (10/32) of women reported ongoing or worse symptoms after Essure removal. All procedures took approximately one hour (mean 65 min, SD 33 min), were associated with minimal blood loss (mean 31 mL, SD 17), and had no perioperative complications.


      Essure removal is a procedure that may be effective for treating most women with symptoms attributed to the device. Patients should be counseled that some symptoms may persist or even worsen following surgery.


      To read this article in full you will need to make a payment
      AAGL Member Login
      AAGL Member, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Bayer Pharmaceuticals. Essure—Permanent birth control. Available at: Accessed February 1, 2017.

        • Dhruva S.S.
        • Ross J.S.
        • Gariepy A.M.
        Revisiting Essure—toward safe and effective sterilization.
        N Engl J Med. 2015; 373: e17
      2. AAGL advisory statement: Essure hysteroscopic sterilization.
        J Minim Invasive Gynecol. 2016; 23: 658-659
        • Yunker A.C.
        • Ritch J.M.
        • Robinson E.F.
        • Golish C.T.
        Incidence and risk factors for chronic pelvic pain after hysteroscopic sterilization.
        J Minim Invasive Gynecol. 2015; 22: 390-394
        • Albright C.M.
        • Frishman G.N.
        • Bhagavath B.
        Surgical aspects of removal of Essure microinsert.
        Contraception. 2013; 88: 334-336
        • Brito L.G.
        • Cohen S.L.
        • Goggins E.R.
        • Wang K.C.
        • Einarsson J.I.
        Essure surgical removal and subsequent symptom resolution: case series and follow-up survey.
        J Minim Invasive Gynecol. 2015; 22: 910-913
        • Casey J.
        • Aguirre F.
        • Yunker A.
        Outcomes of laparoscopic removal of the Essure sterilization device for pelvic pain: a case series.
        Contraception. 2016; 94: 190-192
        • Walter J.R.
        • Ghobadi C.W.
        • Hayman E.
        • Xu S.
        Hysteroscopic sterilization with Essure: summary of the US Food and Drug Administration actions and policy implications for postmarketing surveillence.
        Obstet Gynecol. 2017; 129: 10-19